Mark W. Grinstaff, PhD

Professor, Chemistry

Mark Grinstaff
617.358.3429
590 Commonwealth Ave

Biography

Mark W. Grinstaff is a Distinguished Professor of Translational Research, Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine as well as the Director of the NIH T32 Program in Biomaterials and the Director of the Nanotechnology Innovation Center at Boston University.

Mark received his Ph.D. from the University of Illinois under the mentorship of Professor Kenneth S. Suslick and was an NIH postdoctoral fellow at the California Institute of Technology with Professor Harry B. Gray. Mark’s awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher- Scholar, Alfred P. Sloan Research Fellowship, the Edward M. Kennedy Award for Health Care Innovation, and a Founding Fellow of the National Academy of Inventors. He is an author or co-author on more than 225 peer-reviewed manuscripts, given more than 300 oral presentations, and an inventor or co- inventor on more than 200 issued patents or pending applications. His students and fellows have given more than 125 oral presentations and 350 posters at national and international meetings.

Mark’s current research activities involve the synthesis of new macromolecules and biomaterials, self-assembly chemistry, imaging contrast agents, drug delivery, and wound repair. His group pursues highly interdisciplinary research in the areas of biomedical engineering and macromolecular chemistry. The major goal in these research projects is to elucidate the underlying fundamental chemistry and engineering principles and to use that insight to direct our creative and scientific efforts. In one of their current research projects, they are designing, synthesizing, and characterizing novel dendrimers, termed “biodendrimers,” for tissue engineering and biotechnological applications. Currently, they are evaluating these novel biomaterials for the repair of corneal lacerations, for the delivery of anti-cancer drugs, for the delivery of DNA, and as temporary biodegradable scaffolds for cartilage repair. In a second project, they are creating novel polymeric coatings termed “interfacial biomaterials” that control biology on plastic, metal, and ceramic surfaces. In a third project, they are designing new polymeric films and nanoparticles loaded with anticancer drugs for the prevention of recurrent cancer after surgical resection.

Mark is a co-founder of several companies that are commercializing his ideas, and he has several products being sold and used in the clinic.

Other Positions

  • Director, Nanotechnology Innovation Center (BUnano), Boston University
  • Professor, Biomedical Engineering, Boston University College of Engineering
  • Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine, Medicine, Boston University School of Medicine

Education

  • University of Illinois, PhD
  • Occidental College, AB

Publications

  • Published on 5/8/2019

    Saukko AEA, Turunen MJ, Honkanen MKM, Lovric G, Tiitu V, Honkanen JTJ, Grinstaff MW, Jurvelin JS, Töyräs J. Simultaneous Quantitation of Cationic and Non-ionic Contrast Agents in Articular Cartilage Using Synchrotron MicroCT Imaging. Sci Rep. 2019 May 08; 9(1):7118. PMID: 31068614.

    Read at: PubMed
  • Published on 5/7/2019

    Nelson BB, Mäkelä JTA, Lawson TB, Patwa AN, Barrett MF, Wayne McIlwraith C, Hurtig MB, Snyder BD, Moorman VJ, Grinstaff MW, Goodrich LR, Kawcak CE. Evaluation of Equine Articular Cartilage Degeneration After Mechanical Impact Injury Using Cationic Contrast-Enhanced Computed Tomography. Osteoarthritis Cartilage. 2019 May 07. PMID: 31075424.

    Read at: PubMed
  • Published on 4/15/2019

    Caputo HE, Straub JE, Grinstaff MW. Design, synthesis, and biomedical applications of synthetic sulphated polysaccharides. Chem Soc Rev. 2019 Apr 15; 48(8):2338-2365. PMID: 30742140.

    Read at: PubMed
  • Published on 4/1/2019

    Ekladious I, Colson YL, Grinstaff MW. Polymer-drug conjugate therapeutics: advances, insights and prospects. Nat Rev Drug Discov. 2019 Apr; 18(4):273-294. PMID: 30542076.

    Read at: PubMed
  • Published on 3/28/2019

    Honkanen MKM, Matikka H, Honkanen JTJ, Bhattarai A, Grinstaff MW, Joukainen A, Kröger H, Jurvelin JS, Töyräs J. Imaging of proteoglycan and water contents in human articular cartilage with full-body CT using dual contrast technique. J Orthop Res. 2019 May; 37(5):1059-1070. PMID: 30816584.

    Read at: PubMed
  • Published on 1/30/2019

    Zeng J, Shirihai OS, Grinstaff MW. Degradable Nanoparticles Restore Lysosomal pH and Autophagic Flux in Lipotoxic Pancreatic Beta Cells. Adv Healthc Mater. 2019 Jan 30; e1801511. PMID: 30698920.

    Read at: PubMed
  • Published on 1/29/2019

    Benizri S, Gissot A, Martin A, Vialet B, Grinstaff MW, Barthélémy P. Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications. Bioconjug Chem. 2019 Feb 20; 30(2):366-383. PMID: 30608140.

    Read at: PubMed
  • Published on 1/9/2019

    Beharaj A, Ekladious I, Grinstaff MW. Poly(Alkyl Glycidate Carbonate)s as Degradable Pressure-Sensitive Adhesives. Angew Chem Int Ed Engl. 2019 Jan 28; 58(5):1407-1411. PMID: 30516857.

    Read at: PubMed
  • Published on 1/8/2019

    El-Elimat T, Raja HA, Ayers S, Kurina SJ, Burdette JE, Mattes Z, Sabatelle R, Bacon JW, Colby AH, Grinstaff MW, Pearce CJ, Oberlies NH. Meroterpenoids from Neosetophoma sp.: A Dioxa[4.3.3]propellane Ring System, Potent Cytotoxicity, and Prolific Expression. Org Lett. 2019 Jan 18; 21(2):529-534. PMID: 30620608.

    Read at: PubMed
  • Published on 1/4/2019

    Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, Xie Z, Kulp SK, Coss CC, Phelps MA, Albers T, Lebedyeva IO, Liu K. SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. Cancer Immunol Res. 2019 Mar; 7(3):414-427. PMID: 30610059.

    Read at: PubMed

View 279 more publications: View full profile at BUMC

View all profiles